Senseonics raises $20 mln from existing investors

Anthem Capital, Delphi Ventures, Greenspring Associates, Healthcare Ventures, New Enterprise Associates and other strategic partners participated in a $20 million private equity funding in Senseonics, a medical device company. Senseonics announced Mirasol Panlilio, formerly of Abbott Diabetes Care and LifeScan, has joined the company as vice president of global sales and marketing.

Promedior Raises $21.5 Million

Promedior, a clinical stage biotechnology company has raised $21.5M in a first closing of a Series D financing round. The financing was led by a new investor, Fibrotec Ventures with participation from all of Promedior’s existing venture investors, including Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This […]

Promedior Inks $21.5M

Malvern, Penn.-based Promedior Inc., a clinical stage biotechnology company developing therapeutics for fibroproliferative diseases, has held a $21.5 million first closing of its Series D round.  New investor Fibrotec Ventures led the round, which included existing shareholders Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, Forbion Capital Partners and Easton Capital Investment Group. This new round […]

Catalyst Biosciences Inks $7M from Phizer

Catalyst Biosciences Inc. has sealed a $7 million milestone payment from Pfizer, as part of a research and license agreement between the two companies. Catalyst recently initiated Phase 1 clinical trials for one of its products, designed to help treat hemophilia patients. Privately held Catalyst is backed by investors including Essex Woodlands Health Ventures, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures.

PathoGenetix Seals $7.5M Series B

Woburn, Mass.-based PathoGenetix Inc. has raised $7.5 million in a second closing of its Series B financing round. The company announced a $4 million first closing of the round in August. The latest installment brings the Series B total to $11.5 million. Investors include Ascension Health Ventures, Excel Venture Management, CB Health Ventures, and HealthCare Ventures. PathoGenetix develops genome sequence scanning technology.

Sensors for Medicine and Science Adds $54M

Sensors for Medicine and Science Inc., a Maryland-based medical device company, has raised $54.1 million in Series D financing. New investors Delphi Ventures led the round, which included participation from existing shareholders New Enterprise Associates, HealthCare Ventures, Anthem Capital and Greenspring Associates.

Theraclone Sciences Adds $10.6M to Series B

Theraclone Sciences Inc. has added $10.6 million to its Series B round, closing the financing with a total of $41 million. ARCH Venture Partners, Canaan Partners, MPM Capital, Healthcare Ventures, Alexandria Real Estate Equities, Amgen Ventures and Zenyaku Kogyo participated in the financing. The money will be used to continue clinical and discovery programs.

PathoGenetiX Adds $4M in VC

Woburn, Mass.-based PathoGenetiX Inc., a developer of genome sequence scanning technology, has raised $4 million in a first close of its Series B financing. Excel Venture Management led the round, which also included investments from CB Health Ventures and HealthCare Ventures. The company has sealed commitments for $9.5 million in total Series B financing.

nanoMR Inks $13M

nanoMR Inc. has closed on $13 million from Excel Venture Management, Healthcare Ventures, vSpring Capital, The Dow Chemical Company, and Sun Mountain Capital. Steven Gullans of Excel and Gus Lawlor of Healthcare Ventures will join the board as a result of the round. The money will help nanoMR to develop commercial instruments for the clinical microbiology market, perform clinical studies and prepare for product launch, the company said in a release.

Radius Health Closes $91M Round

Radius Health Inc. said Tuesday that it closed a $91 million third round of financing. The round includes $66 million in equity financing, and a commitment by GE Capital, Healthcare Financial Services and Oxford Finance for a $25 million multi-draw term loan facility. Five new investors–including BB Biotech AG, Brookside Capital, Saints Capital, Nordic Bioscience, and Ipsen Pharma SAS–joined existing investors MPM Capital, BB Biotech Ventures, MPM Bio IV NVS Strategic Fund, The Wellcome Trust, HealthCare Ventures, and Scottish Widows Investment Partnership in the equity portion of the round. Radius Health is based in Cambridge, Mass. Radius also announced that immediately following the initial closing of the financing, it merged with MPM Acquisition Corp., an unlisted public reporting shell company. The combined company will go by the name Radius Health. Radius is a developer of drug therapies for osteoporosis and women’s health.

Crouse to PreCision’s Board

William Crouse is joining the board of directors of PreCision Dermatology Inc., a Rhode Island-based maker of over the counter dermatology products. He is a general partner and former Managing Director of HealthCare Ventures, one of the world’s largest venture capital firms specializing in biotechnology.

HealthCare Ventures Raising Ninth Fund

I recently ran across a regulatory filing from HealthCare Ventures, which has been making early-stage and growth-stage deals since 1985. It suggests that the firm is targeting upwards of $250 million for its ninth fund, which would be a step down from the nearly $380 million raised for Fund VIII in 2005.

More interesting than what’s included in the filing, however, is what’s missing. Namely, managing directors James Cavanaugh and Hal Werner. Both were listed as principals in a Fund VIII filing, but not this time around. They also happen to be HealthCare Ventures’ only investment pros in Princeton, N.J., while the rest are based in Cambridge, Mass. (the new filing lists the Cambridge address, whereas past ones list Princeton).

Seahorse Raises $5 Million

Seahorse Bioscience, Inc., a Billerica, Mass.-based medical instrument company, closed a $5 million round of financing. Investors in the Series D round included Commonwealth Capital Ventures, FLIR Systems Inc, Rock Maple Ventures, Life Sciences Partners, Oxford Bioscience Partners, Healthcare Ventures, New Science Ventures and HLM Venture Partners.

InfaCare Secures Series B

Infacare Pharmaceutical Corp has announced a $28 million private placement of its Series B Preferred Stock, led by HealthCare Ventures with participation from Longitude Capital, FirstMark Capital and Atlas Venture. The Trevose, Pa.-based company specializes in late stake neonatal disease treatments. Press Release: InfaCare Pharmaceutical Corporation, a late stage specialty pharmaceutical company focused on the […]

PE HUB Community

Join the 12525 members of PE HUB to make connections, share your opinion, and follow your favorite authors.

Join the Community

Look Who’s Tweeting

PE HUB News Briefs

RSS Feed Widget